Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

131.50 -0.12 (-0.09%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	638,340
Open	131.25
Bid (Size)	131.42 (200)
Ask (Size)	131.50 (1,500)
Prev. Close	131.62
Today's Range	128.15 - 132.78
52wk Range	49.38 - 131.87
Shares Outstanding	62,577,897
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Protagonist Therapeutics Reports Granting of Inducement Awards

July 01, 2026

From Protagonist Therapeutics

Via ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Awards

June 16, 2026

From Protagonist Therapeutics

Via ACCESS Newswire

Performance

YTD	+50.8%	+50.8%
1 Month	+35.0%	+35.0%
3 Month	+27.8%	+27.8%
6 Month	+56.2%	+56.2%
1 Year	+163.7%	+163.7%

More News

Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum ↗

June 13, 2026

Via Chartmill

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

June 01, 2026

Via ACCESS Newswire

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗

May 29, 2026

Via The Motley Fool

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

Via The Motley Fool

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

May 28, 2026

Via ACCESS Newswire

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

Via The Motley Fool

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Via The Motley Fool

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Via The Motley Fool

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 05, 2026

Via ACCESS Newswire

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

April 28, 2026

Via ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Awards

April 16, 2026

Via ACCESS Newswire

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 28, 2026

Via ACCESS Newswire

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

Via MarketMinute

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

Via The Motley Fool

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Via The Motley Fool

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

Via The Motley Fool

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

March 18, 2026

Via ACCESS Newswire

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

March 02, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

Via ACCESS Newswire

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

Via ACCESS Newswire

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

Via The Motley Fool

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

February 24, 2026

Via ACCESS Newswire

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗

February 16, 2026

Via The Motley Fool

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?

Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?

Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?

The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market

What is the current price of Protagonist Therapeutics, Inc. - Common Stock?

The current price of Protagonist Therapeutics, Inc. - Common Stock is 131.50

When was Protagonist Therapeutics, Inc. - Common Stock last traded?

The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 07/06/26 04:00 PM ET

What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?

The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 8.23B

How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?

Protagonist Therapeutics, Inc. - Common Stock has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.